Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
Clinical trial NCT03127592 · TERMINATED
Trial details
- NCT number
- NCT03127592
- Sponsor
- Apsen Farmaceutica S.A.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-05
- Primary completion
- 2022-07-26
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.